Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: Comparison with other hypoxia-activated prodrugs

Biochemical Pharmacology

Volumn 83, Issue 5, 2012, Pages 574-585

  Hunter, Francis W ^a   Wang, Jingli ^a   Patel, Rita ^a   Hsu, Huai Ling ^a   Hickey, Anthony J R ^b   Hay, Michael P ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

CEN 209; Homologous recombination repair; Hypoxia activated prodrug; Redox cycling; TH 302; Tirapazamine

Indexed keywords

BENZIDINE DERIVATIVE; CEN 209; CEN 309; DNA; FUSED CARBON NITROGEN HETEROCYCLE; HYDROGEN PEROXIDE; HYPOXIA ACTIVATED PRODRUG; NITRO CHLOROMETHYLBENZINDOLINE; PR 104A; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CYTOTOXICITY; DNA REPAIR; HYPOXIA; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHO CELLS; CRICETINAE; CYCLIC N-OXIDES; DNA DAMAGE; DNA REPAIR; GENOTYPE; MOLECULAR STRUCTURE; OXYGEN; PRODRUGS; TRIAZINES;

EID: 84856111945     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.12.005     Document Type: Article

References (80)

1. 2 histography Antioxid Redox Signal 9 2007 1221 1235 (Pubitemid 47080831)
2. J.M. Brown, and A.J. Giaccia The unique physiology of solid tumors: opportunities (and problems) for cancer therapy Cancer Res 58 1998 1408 1416 (Pubitemid 28193601)
3. W.R. Wilson, and M.P. Hay Targeting hypoxia in cancer therapy Nat Rev Cancer 11 2011 393 410
4. W.A. Denny Hypoxia-activated prodrugs in cancer therapy: progress to the clinic Future Oncol 6 2010 419 428
5. A.V. Patterson, D.M. Ferry, S.J. Edmunds, Y. Gu, R.S. Singleton, and K. Patel Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104 Clin Cancer Res 13 2007 3922 3932 (Pubitemid 47037600)
6. J.X. Duan, H. Jiao, J. Kaizerman, T. Stanton, J.W. Evans, and L. Lan Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs J Med Chem 51 2008 2412 2420 (Pubitemid 351628502)
7. M. Tercel, G.J. Atwell, S. Yang, A. Ashoorzadeh, R.J. Stevenson, and K.J. Botting Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins Angew Chem Int Ed 50 2011 2606 2609
8. R.S. Singleton, C.P. Guise, D.M. Ferry, S.M. Pullen, M.J. Dorie, and J.M. Brown DNA crosslinks in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism and cytotoxicity Cancer Res 69 2009 3884 3891
9. Y. Gu, A.V. Patterson, G.J. Atwell, S.B. Chernikova, J.M. Brown, and L.H. Thompson Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A Mol Cancer Ther 8 2009 1714 1723
10. R.F. Anderson, S.S. Shinde, M.P. Hay, S.A. Gamage, and W.A. Denny Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction J Am Chem Soc 125 2003 748 756 (Pubitemid 36109936)
11. G. Chowdhury, V. Junnotula, J.S. Daniels, M.M. Greenberg, and K.S. Gates DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2) J Am Chem Soc 129 2007 12870 12877 (Pubitemid 350004499)
12. G.D. Jones, and M. Weinfeld Dual action of tirapazamine in the induction of DNA strand breaks Cancer Res 56 1996 1584 1590 (Pubitemid 26104022)
13. D. Kotandeniya, B. Ganley, and K.S. Gates Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) Bioorg Med Chem Lett 12 2002 2325
14. S.S. Shinde, R.F. Anderson, M.P. Hay, S.A. Gamage, and W.A. Denny Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides J Am Chem Soc 126 2004 7865 7874 (Pubitemid 38812777)
15. J. von Pawel, R. von Roemeling, U. Gatzemeier, M. Boyer, L.O. Elisson, and P. Clark Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors J Clin Oncol 18 2000 1351 1359 (Pubitemid 30159856)
16. D. Rischin, L. Peters, R. Fisher, A. Macann, J. Denham, and M. Poulsen Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02) J Clin Oncol 23 2005 79 87 (Pubitemid 41702625)
17. D. Rischin, L.J. Peters, B. O'Sullivan, J. Giralt, R. Fisher, and K. Yuen Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group J Clin Oncol 28 2010 2989 2995
18. D. Rischin, R.J. Hicks, R. Fisher, D. Binns, J. Corry, and S. Porceddu Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2006 2098 2104 (Pubitemid 46622121)
19. L.J. Peters, B. O'Sullivan, J. Giralt, T.J. Fitzgerald, A. Trotti, and J. Bernier Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02 J Clin Oncol 28 2010 2996 3001
20. K.O. Hicks, F.B. Pruijn, T.W. Secomb, M.P. Hay, R. Hsu, and J.M. Brown Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs J Natl Cancer Inst 98 2006 1118 1128 (Pubitemid 44288786)
21. K.O. Hicks, B.G. Siim, J.K. Jaiswal, F.B. Pruijn, A.M. Fraser, and R. Patel Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors Clin Cancer Res 16 2010 4946 4957
22. T. Helleday, E. Petermann, C. Lundin, B. Hodgson, and R.A. Sharma DNA repair pathways as targets for cancer therapy Nat Rev Cancer 8 2008 193 204 (Pubitemid 351301852)
23. B. Evers, T. Helleday, and J. Jonkers Targeting homologous recombination repair defects in cancer Trends Pharmacol Sci 31 2010 372 380
24. R.S. Bindra, P.J. Schaffer, A. Meng, J. Woo, K. Maseide, and M.E. Roth Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells Mol Cell Biol 24 2004 8504 8518 (Pubitemid 39245072)
25. N. Chan, M. Koritzinsky, H. Zhao, R. Bindra, P.M. Glazer, and S. Powell Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance Cancer Res 68 2008 605 614 (Pubitemid 351380090)
26. Y. Lu, A. Chu, M.S. Turker, and P.M. Glazer Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter Mol Cell Biol 31 2011 3339 3350
27. J.W. Evans, S.B. Chernikova, L.A. Kachnic, J.P. Banath, O. Sordet, and Y.M. Delahoussaye Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells Cancer Res 68 2008 257 265 (Pubitemid 351380127)
28. C.P. Hart, F. Meng, M. Banica, J. Evans, L. Lan, and G. Lorente In vitro activity profile of the novel hypoxia-activated cytotoxic prodrug TH-302 99th AACR annual meeting 2008 [abstract #1441]
29. 15N NMR assignment of tirapazamine and related 1,2,4-benzotriazine N-oxides Magn Reson Chem 44 2006 948 954 (Pubitemid 44482892)
30. Hay MP, Blaser A, Denny WA, Hicks KO, Lee HH, Pchalek K, et al. Tricyclic 1,2,4-triazine oxides and compositions therefrom for therapeutic use in cancer treatments. Patent EP1866292; 2010.
31. K. Pchalek, and M.P. Hay Stille coupling reactions in the synthesis of hypoxia-selective 3-alkyl-1,2,4-benzotriazine 1,4-dioxide anticancer agents J Org Chem 71 2006 6530 6535 (Pubitemid 44252440)
32. J.H. Worrell, and T.A. Jackman Synthesis and characterization of cobalt(III) complexes derived from a pentadentate ligand having alkylamine and thioether donors to enhance stereospecificity Inorg Chem 17 1978 3358 3361
33. Denny WA, Atwell GJ, Yang S, Wilson WR, Patterson AV, Helsby NA. Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents. PCT/NZ 2004/529249; 2005.
34. L.H. Thompson, S. Fong, and K. Brookman Validation of conditions for efficient detection of HPRT and APRT mutations in suspension-cultured Chinese hamster ovary cells Mutat Res 74 1980 21 36 (Pubitemid 10180124)
35. J.M. Hinz, R.S. Tebbs, P.F. Wilson, P.B. Nham, E.P. Salazar, and H. Nagasawa Repression of mutagenesis by Rad51D-mediated homologous recombination Nucleic Acids Res 34 2006 1358 1383
36. L.H. Thompson, K.W. Brookman, L.E. Dillehay, A.V. Carrano, J.A. Mazrimas, and C.L. Mooney A CHO-cell strain having hypersensitivity to mutagens, a defect in DNA strand-break repair, and an extraordinary baseline frequency of sister-chromatid exchange Mutat Res 95 1982 427 440 (Pubitemid 12095530)
37. D.B. Busch, J.E. Cleaver, and D.A. Glaser Large-scale isolation of UV-sensitive clones of CHO cells Somatic Cell Genet 6 1980 407 418 (Pubitemid 10113597)
38. C.A. Hoy, L.H. Thompson, C.L. Mooney, and E.P. Salazar Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents Cancer Res 45 1985 1737 1743 (Pubitemid 15079132)
39. L.H. Thompson, D.B. Busch, K. Brookman, C.L. Mooney, and D.A. Glaser Genetic diversity of UV-sensitive DNA repair mutants of Chinese hamster ovary cells Proc Natl Acad Sci USA 78 1981 3734 3737 (Pubitemid 11060452)
40. K.W. Brookman, J.E. Lamerdin, M.P. Thelen, M. Hwang, J.T. Reardon, and A. Sancar (XPF) encodes a human nucleotide excision repair protein with eukaryotic recombination homologs Mol Cell Biol 16 1996 6553 6562 (Pubitemid 26361014)
41. L.H. Thompson, J.S. Rubin, J.E. Cleaver, G.F. Whitmore, and K. Brookman A screening method for isolating DNA repair-deficient mutants of CHO cells Somatic Cell Genet 6 1980 391 405 (Pubitemid 10113596)
42. T. Blunt, N.J. Finnie, G.E. Taccioli, G.C. Smith, J. Demengeot, and T.M. Gottlieb Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation Cell 80 1995 813 823
43. R.S. Tebbs, J.M. Hinz, N.A. Yamada, J.B. Wilson, E.P. Salazar, and C.B. Thomas New insights into the Fanconi anemia pathway from an isogenic FancG hamster CHO mutant DNA Repair (Amst) 4 2005 11 22 (Pubitemid 39469078)
44. M.P. Hay, S.A. Gamage, M.S. Kovacs, F.B. Pruijn, R.F. Anderson, and A.V. Patterson Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine J Med Chem 46 2003 169 182 (Pubitemid 36043797)
45. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, and D. Vistica New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1990 1107 1112 (Pubitemid 20213250)
46. A.V. Patterson, M.P. Saunders, E.C. Chinje, D.C. Talbot, A.L. Harris, and I.J. Stratford Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069 Br J Cancer 76 1997 1338 1347 (Pubitemid 27474977)
47. Wang J, Foehrenbacher A, Su J, Patel R, Hay MP, Hicks KO, et al. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate bioreductive prodrug CEN-209 under hypoxia. Clin Cancer Res; in press, doi:10.1158/1078-0432.CCR-11-2296.
48. A.J. Hickey, G.M. Renshaw, B. Speers-Roesch, J.G. Richards, Y. Wang, and A.P. Farrell A radical approach to beating hypoxia: depressed free radical release from heart fibres of the hypoxia-tolerant epaulette shark (Hemiscyllum ocellatum) J Comp Physiol [B] 2011 10.1007/s00360-011-0599-6
49. M. Takata, M.S. Sasaki, E. Sonoda, C. Morrison, M. Hashimoto, and H. Utsumi Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells EMBO J 17 1998 5497 5508 (Pubitemid 28427063)
50. C.P. Guise, A. Wang, A. Thiel, D. Bridewell, W.R. Wilson, and A.V. Patterson Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia Biochem Pharmacol 74 2007 810 820 (Pubitemid 47212075)
51. C. Loveday, C. Turnbull, E. Ramsay, D. Hughes, E. Ruark, and J.R. Frankum Germline mutations in RAD51D confer susceptibility to ovarian cancer Nat Genet 43 2011 879 882
52. W.R. Wilson, S.M. Stribbling, F.B. Pruijn, S.P. Syddall, A.V. Patterson, and H.D.S. Liyanage Nitro-chloromethylindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators Mol Cancer Ther 8 2009 2903 2913
53. P. Rajesh, A.V. Litvinchuk, D.L. Pittman, and M.D. Wyatt The homologous recombination protein RAD51D mediates the processing of 6-thioguanine lesions downstream of mismatch repair Mol Cancer Res 9 2011 206 214
54. S. Jones, R.H. Hruban, M. Kamiyama, M. Borges, X. Zhang, and D.W. Parsons Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene Science 324 2009 217
55. J.E. Cleaver, E.T. Lam, and I. Revet Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity Nat Rev Genet 10 2009 756 768
56. M.E. Churchill, J.G. Peak, and M.J. Peak Correlation between cell survival and DNA single-strand break repair proficiency in the Chinese hamster ovary cell lines AA8 and EM9 irradiated with 365-nm ultraviolet-A radiation Photochem Photobiol 53 1991 229 236
57. M. Birincioglu, P. Jaruga, G. Chowdhury, H. Rodriguez, M. Dizdaroglu, and K.S. Gates DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) J Am Chem Soc 125 2003 11607 11615 (Pubitemid 37210109)
58. K.B. Peters, and Brown J.M. Tirapazamine A hypoxia-activated topoisomerase II poison Cancer Res 62 2002 5248 5253
59. J. Wang, K.A. Biedermann, and J.M. Brown Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation Cancer Res 52 1992 4473 4477
60. J.M. Silva, and P.J. O'Brien Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions Br J Cancer 68 1993 484 491 (Pubitemid 23258450)
61. J.S. Daniels, and K.S. Gates DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233): evidence for involvement of hydroxyl radical J Am Chem Soc 118 1996 3380 3385 (Pubitemid 26145092)
62. S.S. Shinde, M.P. Hay, A.V. Patterson, W.A. Denny, and R.F. Anderson Spin trapping of radicals other than the*OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase J Am Chem Soc 131 2009 14220 14221
63. S.S. Shinde, A. Maroz, M.P. Hay, A.V. Patterson, W.A. Denny, and R.F. Anderson Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4- benzotriazine 1,4-dioxide (tirapazamine) J Am Chem Soc 132 2010 2591 2599
64. J.T. Hwang, M.M. Greenberg, T. Fuchs, and K.S. Gates Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1′-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions Biochemistry (Mosc) 38 1999 14248 14255
65. B.G. Siim, F.B. Pruijn, J.R. Sturman, A. Hogg, M.P. Hay, and J.M. Brown Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317 Cancer Res 64 2004 736 742 (Pubitemid 38120917)
66. C.J. Koch Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin Cancer Res 53 1993 3992 3997 (Pubitemid 23267700)
67. K.O. Hicks, B.G. Siim, F.B. Pruijn, and W.R. Wilson Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors Radiat Res 161 2004 656 666 (Pubitemid 39149574)
68. L.L. Herscher, M.C. Krishna, J.A. Cook, C.N. Coleman, J.E. Biaglow, and S.W. Tuttle Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron Int J Radiat Oncol Biol Phys 30 1994 879 885 (Pubitemid 24355940)
69. A. Cahill, T.C. Jenkins, and I.N. White Metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) by purified DT-diaphorase under aerobic and anaerobic conditions Biochem Pharmacol 45 1993 321 329 (Pubitemid 23042630)
70. S. Khan, and P.J. O'Brien Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations Br J Cancer 71 1995 780 785
71. B.G. Wouters, and J.M. Brown Cells at intermediate oxygen levels can be more important than the hypoxic fraction in determining tumor response to fractionated radiotherapy Radiat Res 147 1997 541 550 (Pubitemid 27204090)
72. I.M. Pires, Z. Bencokova, M. Milani, L.K. Folkes, J.L. Li, and M.R. Stratford Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability Cancer Res 70 2010 925 935
73. D. Branzei, and M. Foiani Maintaining genome stability at the replication fork Nat Rev Mol Cell Biol 11 2010 208 219
74. P.L. Olive, and P.J. Johnston DNA damage from oxidants: influence of lesion complexity and chromatin organization Oncol Res 9 1997 287 294 (Pubitemid 127825982)
75. P.S. Lin, and K.C. Ho New cytotoxic mechanism of the bioreductive agent tirapazamine (SR 4233) mediated by forming complex with copper Radiat Oncol Investig 4 1996 211 220
76. P. Wardman Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia Curr Med Chem 8 2001 739 761 (Pubitemid 32427904)
77. P.A. Konstantinopoulos, D. Spentzos, B.Y. Karlan, T. Taniguchi, E. Fountzilas, and N. Francoeur Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer J Clin Oncol 28 2010 3555 3561
78. M.A. Vollebergh, E.H. Lips, P.M. Nederlof, L.F. Wessels, M.K. Schmidt, and E.H. van Beers An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients Ann Oncol 22 2011 1561 1570
79. M. Graeser, A. McCarthy, C.J. Lord, K. Savage, M. Hills, and J. Salter A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer Clin Cancer Res 16 2010 6159 6168
80. N. Chan, I.M. Pires, Z. Bencokova, C. Coackley, K.R. Luoto, and N. Bhogal Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment Cancer Res 70 2010 8045 8054